← All Cvrx, INC filings

Cvrx, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
CVRX
Cvrx, INC
10-Q: CVRx Reports Q1 2026 Revenue Growth, Net Loss Narrows
CVRx, Inc. announced its first quarter 2026 financial results, showcasing a 20% increase in revenue driven by strong U.S. sales, while also reporting a slight reduction in net loss compared to the prior year period.
NASDAQ
CVRX
Cvrx, INC
10-Q: CVRx Q3 2025: Barostim Drives Revenue Growth Amid Losses
CVRx, Inc. reported a 10% revenue increase in Q3 2025, driven by U.S. Barostim sales and improved gross margins, despite continued net losses.
NASDAQ
CVRX
Cvrx, INC
10-Q: CVRx Reports Strong Revenue Growth Amid Continued Losses
CVRx, Inc. announced a 15% revenue increase for Q2 2025, driven by U.S. Barostim sales, while continuing to incur net losses as it invests in commercialization.
NASDAQ
CVRX
Cvrx, INC
10-Q: CVRx Reports 15% Revenue Increase in Q1 2025, Driven by U.S. Sales Growth
CVRx, Inc. reports a 15% increase in revenue for the first quarter of 2025, primarily driven by growth in U.S. sales of its Barostim device for heart failure.
NASDAQ
CVRX
Cvrx, INC
10-Q: CVRx Reports 27% Revenue Increase in Q3 2024, Driven by U.S. Sales Growth
CVRx, Inc. announced a 27% increase in revenue for the third quarter of 2024, primarily driven by growth in U.S. sales of its Barostim device.
NASDAQ
CVRX
Cvrx, INC
10-Q: CVRx Reports 29% Revenue Increase in Second Quarter, Driven by U.S. Sales Growth
CVRx, Inc. announced a 29% increase in revenue for the second quarter of 2024, primarily driven by strong growth in U.S. sales of its Barostim device.
NASDAQ
CVRX
Cvrx, INC
10-Q: CVRx Reports 35% Revenue Increase in First Quarter 2024, Driven by U.S. Sales Growth
CVRx, Inc. saw a 35% increase in revenue in the first quarter of 2024 compared to the same period last year, primarily driven by growth in U.S. sales of its Barostim device.